Regulatory T cells in cancer therapy
Regulatory T cells in cancer therapy
批准号:
10361528
负责人:
WEIPING ZOU
金额:
$63.44万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30
关键词:
AddressAdenosineAffectAntigen-Presenting CellsApoptosisApoptoticBehaviorBiologyCancer PatientCell CommunicationCell physiologyCellsClinicalClinical ResearchColon CarcinomaDataDendritic CellsDevelopmentDisease modelExhibitsFOXP3 geneFamilyGlucoseGlycolysisHomeostasisHumanImmuneImmune responseImmunityImmunosuppressionImmunotherapyImpairmentLigandsMC38Malignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMediatingMemoryMetabolicMetabolic PathwayMetabolismModelingMolecularMonoclonal AntibodiesMusMyelogenousMyeloid CellsNatureNecrosisNutrientOxidative StressOxygenPD-L1 blockadePathway interactionsPhagocytosisPhenotypeProcollagen-Proline DioxygenaseProductionProteinsRegulationRegulatory T-LymphocyteReportingSignal TransductionSurfaceT memory cellT-Cell ActivationT-LymphocyteTechnologyTestingTranslational ResearchTreatment EfficacyTumor AntigensTumor ImmunityVaccinationWarburg EffectWorkZincantigen-specific T cellsbasecancer immunotherapycancer therapycancer typecheckpoint therapyclinical predictorsdesigneffector T cellempoweredimmunogenicityimprovedmelanomanoveloxidized lipidpotassium ionpractical applicationprogrammed cell death ligand 1receptorrecruitresponsestemsuccesstraffickingtumortumor immunologytumor metabolismtumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Extensive studies have been conducted to define the development, conversion, stability, and regulatory
mechanisms of CD4+Foxp3+ regulatory T cells (Tregs) in homeostasis and a variety of disease models. It is
well-known that Tregs are recruited, converted, and expanded in the tumor microenvironment and act as one
of the major immunosuppressive mechanisms dampening spontaneous tumor-associated antigen (TAA)-
specific T cell immunity and immunotherapy and active vaccination induced anti-tumor immunity. However, how
Tregs behave in the metabolically abnormal tumor microenvironment remains unknown.
The Warburg effect is an important metabolic feature in many types of cancer. Given that nutrients including
glucose are poorly replenished in the tumor, it is assumed that T cell glycolytic metabolism has been altered
due to the Warburg effect in the tumor microenvironment. In support of this, poor glycolysis can alter effector
memory T cell function in the tumor microenvironment. In addition, the oxygen-sensing prolyl-hydroxylase
proteins, necrotic cells released potassium ions, and abnormal zinc metabolism can impair effector T cell
function in the tumor microenvironment. These studies underscore the significance of metabolic regulation of
memory T cells in the tumor.
Tregs exhibit a memory and effector phenotype in the human tumor microenvironment. It is unknown whether
Tregs are subject to glycolytic regulation in the tumor. Furthermore, oxidative stress is an additional metabolic
feature in the tumor microenvironment. Myeloid dendritic cells (DCs) are phenotypically and functionally altered
by oxidative stress in the tumor microenvironment. However, it is unknown whether oxidative stress alters Treg
phenotype and function in the tumor and affects cancer immunotherapy. To address these questions, we have
examined the phenotypic and functional nature of Tregs in human ovarian cancer and several types of mouse
cancer. We have found that Tregs are highly apoptotic in the tumor microenvironment. Interestingly, apoptotic
Tregs are superior suppressors via a distinct mechanism. Furthermore, oxidative stress, rather than glycolysis,
is a metabolic mechanism controlling tumor Treg functional behavior and tempering therapeutic efficacy of
immune checkpoint therapy. This project is to conduct comprehensive molecular, functional, translational, and
clinical research on the nature of Tregs and their metabolic pathway in the cancer microenvironment. We will
provide rich opportunities to take our understanding of Treg biology in the tumor to a new level of basic and
practical application. Our specific aims are:
Aim 1 is to test our hypothesis that oxidative stress controls Treg apoptosis in the tumor
microenvironment. Aim 2 is to determine the molecular mechanisms controlling the energy circuit
of Tregs and the interaction between Tregs and APCs in tumor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CTL-killing capacity and cancer stiffness in cancer immunity and therapy
-
批准号:10548120
-
项目类别:
-
资助金额:$63.44万
-
财政年份:2022
-
负责人:WEIPING ZOU
-
依托单位:
CTL-killing capacity and cancer stiffness in cancer immunity and therapy
-
批准号:10274980
-
项目类别:
-
资助金额:$64.74万
-
财政年份:2022
-
负责人:WEIPING ZOU
-
依托单位:
Regulatory T cells in cancer therapy
-
批准号:10209436
-
项目类别:
-
资助金额:$64.73万
-
财政年份:2021
-
负责人:WEIPING ZOU
-
依托单位:
Regulatory T cells in cancer therapy
-
批准号:10652255
-
项目类别:
-
资助金额:$63.43万
-
财政年份:2021
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10430013
-
项目类别:
-
资助金额:$63.35万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10159227
-
项目类别:
-
资助金额:$64.64万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10650404
-
项目类别:
-
资助金额:$63.34万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Ovarian Cancer Epigenetics, Immunity and Therapy
-
批准号:10408767
-
项目类别:
-
资助金额:$59.88万
-
财政年份:2018
-
负责人:WEIPING ZOU
-
依托单位:
Ovarian Cancer Epigenetics, Immunity and Therapy
-
批准号:10163133
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2018
-
负责人:WEIPING ZOU
-
依托单位:
Immune Impact on Cancer Chemoresistance
-
批准号:9207664
-
项目类别:
-
资助金额:$60.99万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:10199954
-
项目类别:
-
资助金额:$64.72万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:10411383
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:9348840
-
项目类别:
-
资助金额:$61.38万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Immune Impact on Cancer Chemoresistance
-
批准号:9397538
-
项目类别:
-
资助金额:$61.19万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:9752498
-
项目类别:
-
资助金额:$61.47万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
MDSCs in Ovarian Cancer
-
批准号:9288150
-
项目类别:
-
资助金额:$49.83万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Effector T Cell Trafficking in Ovarian Cancer
-
批准号:9014531
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Effector T Cell Trafficking in Ovarian Cancer
-
批准号:9220730
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Immune Regulation in the Microenvironment of Oropharyngeal Cancer
-
批准号:8577165
-
项目类别:
-
资助金额:$53.47万
-
财政年份:2013
-
负责人:WEIPING ZOU
-
依托单位:
Immune Regulation in the Microenvironment of Oropharyngeal Cancer
-
批准号:8692679
-
项目类别:
-
资助金额:$51.86万
-
财政年份:2013
-
负责人:WEIPING ZOU
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: